NCT04265651: An ongoing trial by QED Therapeutics, a BridgeBio company
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04265651 |
|---|---|
| Title | Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2 |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 10, 2020 |
| Completion date | Oct. 21, 2024 |
| Required reporting date | Oct. 21, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |